Method for producing marine algae-derived agarotriose, and use thereof as prebiotic

ABSTRACT

The present invention relates to a method for producing marine algae-derived agarotriose, and a use thereof as a prebiotic. More specifically, the present invention investigates the characteristics of agarotriose as a prebiotic which is selectively metabolized by probiotic microorganisms, thereby enabling agarotriose to be used as an anti-cancer or anti-inflammatory agent in the fields of food and pharmaceuticals, and enabling agarotriose to be obtained at high yield through efficient purification with minimal loss after enzymatic hydrolysis of a red algae-derived polysaccharide without pre-treatment.

BACKGROUND 1. Field of the Invention

The present invention relates to a method for producing marine algae-derived agarotriose, and a use thereof as a prebiotic.

2. Discussion of Related Art

Prebiotics refer to materials that are selectively fermented by intestinal beneficial bacteria to improve intestinal flora and are beneficial for human health. While studies on the correlation between human diseases and intestinal flora have been recently reported, intestinal flora has been recognized as a second human genome, so that studies in this field have been rapidly developed. In particular, as there are study results reporting that as the distribution of intestinal beneficial flora is increased, obesity, diabetes, and immune functions are improved, research on intestinal flora has been getting more attention.

The prebiotic effect of hydrolysis products of agarose which is a main polysaccharide constituting red algae has been predicted through animal experiments. As a result of orally administering an agarooligosaccharide mixture to rats with obesity induced by a high fat diet, it was confirmed that the degree of distribution of Bifidobacteria which is an intestinal beneficial bacteria was increased. In addition, the agarooligosaccharide mixture promoted synthesis of intestinal low-molecular weight fatty acids and induced expression of immune and anti-inflammatory function-related genes. Further, it was confirmed that in the case of a neoagarooligosaccharide mixture produced from agarose by two types of endo-type β-agarase enzymatic reactions, Bifidobacteria and Lactobacillus were growing under carbon source condition of a neoagarooligosaccharide mixture. However, in this experiment, since a growth test of Bifidobacteria and Lactobacillus was not performed under a condition in the absence of a neoagarooligosaccharide mixture as a control, there is a problem in that it cannot be exactly known whether the growth is caused by other carbon sources in the medium or by the metabolism of the neoagarooligosaccharide. Further, it was confirmed that when the neoagarooligosaccharide mixture was administered to a rat model, the degree of distribution of Bifidobacteria and Lactobacillus was increased.

As previously described, since the prebiotics functionality studies of red algae-derived oligosaccharides have used a mixture rather than a purified standard material to date, it is not known at all what effective index components impart a change in the intestinal flora while actually having prebiotic activity. In addition, it is not known how agarose-derived oligosaccharides are metabolized by intestinal effective probiotic microorganisms.

Meanwhile, the main polysaccharide constituting red algae is agarose, and agarose is a polymer in which 3,6-anhydro-L-galactose (hereinafter, referred to as ‘3,6-AHG’) and D-galactose (hereinafter, referred to as ‘D-Gal’) are alternately linked together through alpha-1,3-bonds and β-1,4-bonds. A previous study established a process for the production of AHG with anti-caries, anti-inflammatory, whitening, and moisturizing functions. Agarooligosaccharides were obtained by pre-treatment of a substrate such as an agarose or agar substrate using a weak acid, acetic acid or a low-concentration neutral buffer, Tris-HCl buffer (pH 7.4), and neoagarobiose was produced from the agarooligosaccharides through an exo-type β-agarase II enzymatic reaction. In this case, there is a disadvantage in that agarotriose is also produced as a byproduct, and in order to degrade agarotriose into a monosaccharide AHG and galactose, there is a need for introducing an additional enzyme called agarolytic β-galactosidase (ABG). However, agarotriose in the form of Gal-AHG-Gal, which is an oligosaccharide that was considered as a byproduct for the production of AHG in previous studies is currently known to promote beneficial bacteria in the intestinal function of the body and have prebiotic effects by itself through various documents, but a detailed process technology for obtaining purified and pure agarotriose is not known domestically.

SUMMARY OF THE INVENTION

An object of the present invention is to provide a use of agarotriose as a medicine or food material by investigating the metabolism of agarotriose by intestinal effective probiotic microorganisms.

Another object of the present invention is to provide a method for preparing agarotriose by enzymatic hydrolysis and purification.

To achieve the objects, the present invention provides a medicine composition including: one or more substrates selected from the group consisting of agar, agarose, neoagarohexaose, and agarotriose; a Bacteroides plebeius strain; and a Bifidobacterium strain.

The present invention also provides a method for treating cancer or an inflammatory disease, the method including: administering a therapeutically effective amount of the medicine composition to a subject.

The present invention also provides a food composition including: one or more substrates selected from the group consisting of agar, agarose, neoagarohexaose, and agarotriose; a Bacteroides plebeius strain; and a Bifidobacterium strain.

The present invention also provides a method for preparing agarotriose, the method including:

reacting a reaction product with a neoagarobiose hydrolase of SEQ ID NO: 2 or 6, wherein the reaction product is obtained by reacting any one substrate of agar, agarose or neoagaroheaose with a β-agarase of SEQ ID NO: 1 or 5; and

purifying agarotriose from the resulting product through a size-exclusion column.

The present invention has an effect that the present invention can be used as an anti-cancer or anti-inflammatory material in the fields of medicine and food by investigating the characteristics of agarotriose as a prebiotic which is selectively metabolized by probiotic microorganisms such as Bacteroides and Bifidobacterium.

Further, the present invention has an effect of enabling agarotriose to be obtained at high yield through efficient purification with minimal loss after enzymatic hydrolysis of a red algae-derived polysaccharide without pre-treatment.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates a schematic view for producing oligosaccharides with various degrees of polymerization, neoagarobiose, and AHG from agarose through an enzymatic reaction.

FIG. 2 illustrates the results (A) of purifying recombinant proteins of a Saccharophagus degradans (S. degradans) 2-40^(T)-derived endo type β-agarase Aga16B, an exo type β-agarase Aga50D, and an alpha-neoagarobiose hydrolase SdNABH, the results (B) of producing oligosaccharides with various degrees of polymerization, neoagarobiose, and 3,6-AHG from agarose through an enzymatic reaction, and results (C) of purifying sugars through size-exclusion chromatography of enzyme reaction products of agarose with a Bacteroides plebeius DSM 17135-derived endo type β-agarase enzyme BpGH16A (BACPLE_01670) and a neoagarobiose hydrolase BpGH117 (BACPLE_01671).

FIG. 3 illustrates the results (A) of purifying each recombinant enzyme of intestinal microorganism Bacteroides plebeius DSM 17135-derived endo type β-agarase enzymes BpGH16A (BACPLE_01670) and BpGH50 (BACPLE_01683) and neoagarobiose hydrolase BpGH117 (BACPLE_01671) after being expressed in E. coli and results (B) of performing enzymatic reaction experiments.

FIG. 4 illustrates the results of producing agarotriose and AHG through an enzymatic reaction of a Bacteroides plebeius DSM 17135-derived endo type β-agarase enzyme BpGH16A (BACPLE_01670) and a neoagarobiose hydrolase BpGH117 (BACPLE_01671) from an agarose substrate.

FIG. 5 illustrates the results of culturing a Bifidobacterium longum subsp. infantis ATCC 15697 strain which is a probiotic microorganism with respective purified sugars as carbon sources, using Bioscreen C (A: AHG, B: NeoDP2, C: AgaDP3, D: NeoDP4, E: AgaDP5, F: NeoDP6, G: Glucose, H: Galactose, I: 2FL).

FIG. 6 illustrates the results of analyzing agarotriose fermentation profiles of a Bifidobacterium longum subsp. infantis ATCC 15697 strain (A: results using AgaDP3, NeoDP2, and galactose as a substrate, B: cell density and acetate and lactate as a substrate).

FIG. 7 illustrates the degradation experimental results of agarotriose (A) and neoagarobiose (B) using a crude enzyme solution of a Bifidobacterium longum subsp. infantis ATCC 15697 strain.

FIG. 8 illustrates the results of performing an enzymatic reaction after cloning four β-galactosidase-encoding genes (Blon_2016, Blon_2123, Blon_2334, and Blon_2416) of a Bifidobacterium longum subsp. infantis ATCC 15697 strain and producing and purifying recombinant proteins from E. coli (A: Gel photograph, B: TLC results, C: β-galactosidase specific activity of respective enzymes for an agarotriose substrate).

FIG. 9 illustrates the experimental results of the fermentation ability of agarotriose by Bifidobacterium longum subsp. infantis ATCC 17930 and Bifidobacterium longum subsp. infantis ATCC 15702 strains which are other strains belonging to Bifidobacterium longum subsp. Infantis (A: Bifidobacterium longum subsp. infantis ATCC 17930, B: Bifidobacterium longum subsp. infantis ATCC 15702).

FIG. 10 illustrates the experimental results of the fermentation ability of agarotriose by B. bifidum DSM 20082 and B. kashiwanohense DSM 21854 strains to ferment agarotriose (A: B. bifidum DSM 20082, B: B. kashiwanohense DSM 21854).

FIG. 11 illustrates the stability test results of agarotriose against artificial gastric juice (A: illustrates TLC results as a graph, B: HPLC results).

FIG. 12 illustrates the metabolic pathway of agarose by intestinal microorganisms Bacteroides plebeius DSM 17135 and Bifidobacterium longum subsp. infantis ATCC 15697.

FIG. 13 illustrates a schematic view of a process of producing and isolating agarotriose from agarose (A: process of producing agarotriose through acid treatment and enzymatic saccharification, B: process of producing and purifying AHG, D-Gal, and agarotriose through enzymatic saccharification).

FIG. 14 illustrates the production of agarotriose from agarose through a two-step enzymatic reaction and the results of purifying agarotriose using a size-exclusion column (A: TLC results, B: HPLC results).

FIG. 15 is an HPLC quantitative analysis result showing the ratio of neoagarotetraose and neoagarobiose that are produced from agarose through an enzymatic reaction of a Bacteroides plebeius DSM 17135-derived endo type β-agarase enzyme BpGH16A (BACPLE_01670).

FIG. 16 illustrates the TLC results of analyzing the difference in degree of isolation for each fraction using a size-exclusion column.

FIG. 17 illustrates the results of measuring the yield and purity of agarotriose using an HPLC KS-802 sugar column.

DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS

The present inventors proved the prebiotic effect of agarotriose by producing agarotriose from agarose which is a main carbohydrate constituting red algae through endo type β-agarase and neoagarobiose hydrolase reactions, purely isolating and purifying only agarotriose among enzymatic reaction products using a size-exclusion chromatography technique, and testing the fermentation ability of agarotriose by probiotic Bifidobacteria. Further, since neoagarobiose produced by fermentation of agarotriose by Bifidobacteria may be degraded into galactose and 3,6-AHG by a neoagarobiose hydrolase from Bacteroides plebeius which is an intestinal microorganism and the AHG is a bioactive material having prevention of colon cancer and anti-inflammatory effects, it was confirmed that agarotriose could be expected to have not only prebiotic activity but also biological activities such as anti-cancer and anti-inflammation through metabolism by intestinal microorganisms.

Therefore, the present invention provides a medicine composition including: one or more substrates selected from the group consisting of agar, agarose, neoagarohexaose, and agarotriose; a Bacteroides plebeius strain; and a Bifidobacterium strain.

The Bacteroides plebeius strain may include a Bacteroides plebeius DSM 17135 strain.

The Bifidobacterium strain may include Bifidobacterium longum subsp. infantis ATCC 17930, Bifidobacterium longum subsp. infantis ATCC 15702, B. bifidum DSM 20082, B. kashiwanohense DSM 21854, or the like.

The medicine composition of the present invention is characterized in that a substrate is finally degraded into 3,6-AHG by a Bacteroides plebeius strain and a Bifidobacterium strain.

More specifically, 3,6-AHG may be degraded from a substrate by a 62-agarase of SEQ ID NO: 1 and a neoagarobiose hydrolase of SEQ ID NO: 2 derived from Bacteroides plebeius DSM 17135 strain, respectively and a β-galactosidase of SEQ ID NO: 3 or 4 derived from Bifidobacterium longum subsp. infantis ATCC 15697 strain.

The β-agarase is an enzyme which is derived from Bacteroides plebeius DSM 17135 and uses agar, agarose, or neoagarohexaose as a substrate to degrade the substrate into neoagarotetraose and neoagarobiose, and may be represented by the amino acid sequences of SEQ ID NO: 1.

The β-agarase may be transcribed and translated through not only a region before and after a coding region of the enzyme, but also a DNA segment associated with production of a polypeptide including an intervening sequence between individual coding segments, that is, a coding gene. Further, a protein having a hydrolytic activity of the agar, agarose, or neoagarohexaose as a variant protein with one or more of substitution, deletion, transposition, addition, and the like of the enzyme is also included in the scope of the enzyme of the present invention, and preferably, includes an amino acid sequence having a sequence identity of 80% or more, 85% or more, 90% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, and 99% or more with the amino acid sequences set forth in SEQ ID NO: 1.

The β-agarase may be isolated and purified from a supernatant of a Bacteroides plebeius DSM 17135 cultures, and may be produced and isolated from strains other than Bacteroides plebeius DSM 17135 using a genetic engineering recombinant technology, an artificial chemical synthesis method, or the like. When the genetic engineering recombinant technology is used, it may be replaced by a supernatant or supernate fluid of a culture product of a transformed E. coli, but the technology is not particularly limited thereto. According to a specific exemplary embodiment, the β-agarase may be obtained from E. coli transformed with a recombinant vector including a nucleic acid sequence of a gene encoding the βagarase, or cultures thereof.

The neoagarobiose hydrolase is an enzyme that is derived from Bacteroides plebeius DSM 17135 and uses neoagarotetraose or neoagarobiose as a substrate to degrade the substrate into agarotriose, galactose, or 3,6-anhydro-L-galactose, and may be represented by the amino acid sequences of SEQ ID NO: 2.

The neoagarobiose hydrolase may be transcribed and translated through not only a region before and after a coding region of the neoagarobiose hydrolase, but also a DNA segment associated with production of a polypeptide including an intervening sequence between individual coding segments, that is, a coding gene. Further, a protein having a hydrolytic activity of the agar, agarose, or neoagarohexaose as a variant protein with one or more of substitution, deletion, transposition, addition, and the like of the enzyme is also included in the scope of the enzyme of the present invention, and preferably, includes an amino acid sequence having a sequence identity of 80% or more, 85% or more, 90% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, and 99% or more with the amino acid sequences disclosed in SEQ ID NO: 2.

The neoagarobiose hydrolase may be isolated and purified from a supernatant of a Bacteroides plebeius DSM 17135 cultures, and may be produced and isolated from strains other than Bacteroides plebeius DSM 17135 using a genetic engineering recombinant technology, an artificial chemical synthesis method, or the like. When the genetic engineering recombinant technology is used, it may be replaced by a supernatant or supernate fluid of a culture product of a transformed E. coli, but the technology is not particularly limited thereto. According to a specific exemplary embodiment, the neoagarobiose hydrolase may be obtained from E. coli transformed with a recombinant vector including a nucleic acid sequence of a gene encoding the neoagarobiose hydrolase, or cultures thereof.

The β-galactosidase is an enzyme which is derived from Bifidobacterium longum subsp. infantis ATCC 15697 and degrades agarotriose into neoagarobiose and galactose, is a protein produced from a Blon_2016, Blon_2334 gene, and may be represented by the amino acid sequences of SEQ ID NO: 3 or 4.

The β-galactosidase may be transcribed and translated through not only a region before and after a coding region of the enzyme, but also a DNA segment associated with production of a polypeptide including an intervening sequence between individual coding segments, that is, a coding gene. Further, a protein having a hydrolytic activity of the agarotriose as a variant protein with one or more of substitution, deletion, transposition, addition, and the like of the enzyme is also included in the scope of the enzyme of the present invention, and preferably, includes an amino acid sequence having a sequence identity of 80% or more, 85% or more, 90% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, and 99% or more with the amino acid sequences disclosed in SEQ ID NO: 3 or 4.

The β-galactosidase may be isolated and purified from a supernatant of a Bifidobacterium longum subsp. infantis ATCC 15697 cultures, and may be produced and isolated from strains other than Bifidobacterium longum subsp. infantis ATCC 15697 using a genetic engineering recombinant technology, an artificial chemical synthesis method, or the like. When the genetic engineering recombinant technology is used, it may be replaced by a supernatant or supernate fluid of a culture product of a transformed E. coli, but the technology is not particularly limited thereto. According to a specific exemplary embodiment, the β-agarase may be obtained from E. coli transformed with a recombinant vector including a nucleic acid sequence of a gene encoding the β-agarase, or cultures thereof.

In the present specification, “protein” and “polypeptide” are used interchangeably.

In the present invention, the fact that a polypeptide has a specific proportion of sequence identity (for example, 80%, 85%, 90%, 95%, or 99%) with another sequence means that when the two sequences are aligned, the amino acid residues are the same as each other at the proportion at the time of comparing the sequences. The alignment and percent homology or identity may be determined by using those described in any suitable software program publicly known in the art, for example, a document [CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (F. M. Ausubel et al., (eds) 1987 Supplement 30 section 7.7.18)]. Examples of a preferred program include a GCG Pileup program, FASTA (Pearson et al., 1988 Proc. Natl Acad. Sci USA 85:2444-2448), and BLAST (BLAST Manual, Altschul et al., Natl. Cent. Biotechnol. Inf., Natl Lib. Med. (NCIB NLM NIH), Bethesda, Md., and Altschul et al., 1997 NAR25:33893402). Another preferred alignment program is ALIGN Plus (Scientific and Educational Software, Pa.), and preferably, is an alignment program which uses base parameters. Another available sequence software program is a TFASTA Data Searching Program available in the Sequence Software Package Version 6.0 (Genetics Computer Group, University of Wisconsin, Madison, Wis.).

As used herein, the term “recombinant” when used in connection with a cell, a nucleic acid, a protein, or a vector indicates that the cell, the nucleic acid, the protein, or the vector is modified by introducing a heterologous nucleic acid or protein or changing an original nucleic acid or protein, or that the cell is derived from a cell thus modified. That is, for example, a recombinant cell expresses a gene which is not found within the original (non-recombinant) form of the cell, or alternatively, the recombinant cell expresses an original gene which is abnormally expressed or not expressed at all upon expression.

In the present specification, “nucleic acid” encompasses single stranded or double stranded DNA and RNA, and a chemical variant thereof “Nucleic acid” and “polynucleotide” may be used interchangeably in the present application. Since the genetic code is degenerate, one or more codons may be used in order to encode a specific amino acid, and the present invention encompasses a polynucleotide encoding a specific amino acid sequence.

The term “introduction” in which a nucleic acid sequence is inserted into a cell means “transfection”, or “transformation” or “transduction”, and the reference to the integration of a nucleic acid sequence into an eukaryotic cell or a prokaryotic cell is included, and in this case, the nucleic acid sequence is integrated into a genome (for example, a chromosome, a plasmid, a choromatophore, or mitochondrial DNA) of a cell, and thus is converted into an autonomous replicon, or transiently expressed.

The medicine composition of the present invention metabolizes agar, agarose, neoagarohexaose, or agarotriose into 3,6-AHG having anti-inflammatory and anti-cancer activities, and thus may be used for preventing or treating cancer or an inflammatory disease.

As used herein, the term “prevention” refers to all actions that suppress or delay the onset of cancer or an inflammatory disease by administering the medicine composition of the present invention to a subject.

As used herein, the term “treatment” refers to all actions that ameliorate or beneficially change symptoms of cancer or an inflammatory disease by administering the medicine composition of the present invention to a subject.

As used herein, ‘effective amount’ refers to an amount of a compound capable of exhibiting an anti-cancer effect or suppressing inflammation.

The cancer may be colon cancer, cervical cancer, breast cancer, gastric cancer, liver cancer, and the like.

As used herein, ‘anti-inflammatory effect’ or ‘anti-inflammatory activity’ refers to the suppression of inflammation, and the inflammation is one of the defense responses of a living tissue to a certain stimulus, and refers to a complicated lesion involving three things: tissue degeneration, circulatory disturbance and exudation, and tissue proliferation. More specifically, inflammation is part of innate immunity, and human innate immunity recognizes cell surface patterns specifically present in pathogens, like in other animals. Phagocytes recognize cells having such surfaces as non-self and attack pathogens. If pathogens break through the physical barriers of the body, an inflammatory response occurs. The inflammatory response is a non-specific defense action that creates a hostile environment for the microorganisms that have invaded a wound site. In the inflammatory response, when a wound occurs or an external infectious agent enters the body, the leukocytes responsible for the immune response in the initial stage cluster and express cytokines. Therefore, the expression level of intracellular cytokines is an index of inflammatory response activation.

The inflammatory disease includes general inflammatory symptoms such as edema, and may include inflammatory bowel disease, peritonitis, osteomyelitis, cellulitis, pancreatitis, traumatic shock, bronchial asthma, allergic rhinitis, cystic fibrosis, acute bronchitis, chronic bronchitis, acute bronchiolitis, chronic bronchiolitis, osteoarthritis, gout, spondyloarthropathy, ankylosing spondylitis, Reiter's syndrome, psoriatic arthropathy, enteropathic spondylitis, juvenile arthropathy, juvenile ankylosing spondylitis, reactive arthropathy, infectious arthritis, post-infectious arthritis, gonococcal arthritis, tuberculous arthritis, viral arthritis, fungal arthritis, syphilitic arthritis, Lyme disease, arthritis associated with ‘vasculitis syndrome’, polyarteritis nodosa, hypersensitivity vasculitis, Lou Gehrig's granulomatosis, polymyalgia rheumatica, articular cell arteritis, calcium crystal deposition arthropathy, pseudogout, non-joint rheumatism, bursitis, tenosynovitis, epicondylitis (tennis elbow), neuropathic joint disease (or referred to as ‘Charcot joint’), hemarthrosis, Henoch-Schonlein purpura, hypertrophic osteoarthropathy, multicentric reticulohistiocytoma, scoliosis, hemochromatosis, hemoglobinopathy, hyperlipoproteinemia, hypogammaglobulinemia, familial Mediterranean fever, Behcet's disease, systemic lupus erythematosus, relapsing fever, multiple sclerosis, sepsis, septic shock, acute respiratory distress syndrome, multiple organ dysfunction syndrome, chronic obstructive pulmonary disease, rheumatoid arthritis, acute lung injury, bronchopulmonary dysplasia, diabetes mellitus type II, arteriosclerosis, dementia of Alzheimer's type, familial cold autoinflammatory syndrome, Muckle-Wells syndrome, neonatal multisystem inflammatory disease, chronic infantile neurologic cutaneous articular syndrome, adult-onset Still's disease, contact dermatitis, hydatidiform mole, syndrome of pyogenic arthritis, pyoderma gangrenosum, and acne, hyperimmunoglobulin D syndrome, cryopyrin-associated periodic syndrome, and the like.

The medicine composition of the present invention may further include a pharmaceutically acceptable carrier.

The pharmaceutically acceptable carrier includes a carrier and a vehicle typically used in the medical field, and specific examples thereof include an ion exchange resin, alumina, aluminum stearate, lecithin, a serum protein (for example, a human serum albumin), a buffer material (for example, various phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixture of saturated vegetable fatty acid), water, a salt or electrolyte (for example, protamine sulfate, dissodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, and zinc salts), colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, a cellulose-based substrate, polyethylene glycol, sodium carboxymethylcellulose, polyarylate, wax, polyethylene glycol, wool, or the like, but are not limited thereto.

In addition, the medicine composition of the present invention may additionally include a lubricant, a wetting agent, an emulsifier, a suspending agent, a preservative, or the like, in addition to the aforementioned ingredients.

As an aspect, the medicine composition of the present invention may be formulated and used in various dosage forms suitable for oral or parenteral administration.

Non-limiting examples of the preparations for oral administration include troches, lozenges, tablets, aqueous suspensions, oily suspensions, prepared powders, granules, emulsions, hard capsules, soft capsules, syrups, elixirs, or the like.

To formulate the medicine composition of the present invention for use for oral administration, a binder such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose, or gelatin; an excipient such as dicalcium phosphate; a disintegrating agent such as corn starch or sweet potato starch; a lubricant such as magnesium stearate, calcium stearate, sodium stearyl fumarate, or polyethylene glycol wax; or the like may be used, and a sweetener, a fragrance, syrup, or the like may also be used.

Furthermore, in the case of capsules, in addition to the above-mentioned materials, liquid carriers such as fatty oils may be further used.

Non-limiting examples of the preparations for parenteral administration include injections, suppositories, respiratory inhalation powders, aerosols for spray, oral sprays, oral cleansers, toothpastes, ointments, powder for application, oils, creams, and the like.

To formulate the medicine composition of the present invention for use for parenteral administration, sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, agents for external application, or the like may be used, and as the non-aqueous solvents and the suspensions, propylene glycol, polyethylene glycol, a vegetable oil such as olive oil, an injectable ester such as ethyl oleate, or the like may be used.

In addition, more specifically, when the medicine composition of the present invention is formulated as an injection, the medicine composition of the present invention may be mixed in water with a stabilizer or a buffer to be prepared into a solution or a suspension, which is then formulated into a unit dosage form such as an ampoule or a vial. In addition, when the medicine composition of the present invention is formulated as an aerosol, a propellant or the like may be mixed with an additive to disperse a water-dispersed concentrate or wet powder.

In addition, when the medicine composition of the present invention is formulated as an ointment, a cream, or the like, the medicine composition may be formulated using, as a carrier, an animal oil, a vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, or the like.

A pharmaceutically effective amount and an effective dose of the medicine composition of the present invention may vary depending on the formulation method, administration mode, administration schedule and/or administration route, or the like, and may vary depending on various factors including the type and degree of the reaction to be achieved via administration of the medicine composition of the present invention, the type, age, body weight, and general health status of an individual to which the composition is administrated, the symptoms or severity of diseases, gender, diet, excretion, drugs used simultaneously or at different times in the corresponding individual, ingredients of other compositions, and the like and similar factors well known in the medical field, and the effective dose for desired treatment may be easily determined and prescribed by a person with ordinary skill in the art. The medicine composition of the present invention may be administered once or several times daily. Thus, the dose is not intended to limit the scope of the present invention in any way.

The administration route and administration mode of the medicine composition of the present invention may be independent from each other, the administration method is not particularly limited, and the administration route and the administration mode may follow an arbitrary administration route and administration mode as long as they enable the medicine composition to reach the corresponding site to be targeted. The medicine composition may be administered orally or parenterally.

The parenteral administration may use, for example, intravenous administration, intraperitoneal administration, intramuscular administration, transdermal administration, subcutaneous administration, or the like, a method for applying or spraying the medicine composition on a disease site, or inhaling the medicine composition may also be used, but the methods are not limited thereto.

The medicine composition of the present invention may be preferably administered orally or by injection.

The present invention also provides a method for treating cancer or an inflammatory disease, the method including: administering a therapeutically effective amount of the medicine composition to a subject.

As used herein, the term “subject” refers to all animals including mammals including rats, livestock, humans, and the like.

In a method for treating cancer or an inflammatory disease of the present invention, the description on the dosage, administration route, administration mode, and the like of the medicine composition is the same as that described above in relation to the medicine composition. Further, the type of cancer or inflammatory disease is also the same as that described above in relation to the medicine composition.

The present invention also provides a food composition including: one or more substrates selected from the group consisting of agar, agarose, neoagarohexaose, and agarotriose; a Bacteroides plebeius strain; and a Bifidobacterium strain.

The food composition may be prepared into a food formulation prepared by encapsulation, pulverization, suspension or the like.

Since the food dosage form can be taken on a daily basis, the food dosage form can be expected to prevent or alleviate cancer or an inflammatory disease, and is very useful.

The type of food is not particularly limited and includes, for example, dairy products, health foods in a typical sense, and the like.

The present invention also provides a method for preparing agarotriose, the method including:

reacting a reaction product with a neoagarobiose hydrolase of SEQ ID NO: 2 or 6, wherein the reaction product is obtained by reacting any one substrate of agar, agarose or neoagaroheaose with a β-agarase of SEQ ID NO: 1 or 5; and

purifying agarotriose from the resulting product through a size-exclusion column.

In case of the conventional process (FIG. 13A), in which an enzymatic hydrolysis is performed after a weak acid pre-treatment, produces large amounts of salts in the neutralization process and when a low-concentration neutral buffer is used, a pre-treatment reaction needs to be performed at a high temperature (170° C.), so that a high-temperature and high pressure reactor is required. In addition, the production yield of agarotriose is considerably low due to the focus on improvement of the production yield of 3,6-AHG, and particularly, acetic acid used for the pre-treatment causes an unpleasant odor. For such reasons, there may be problems in using agarotriose as a prebiotic material. Therefore, the method for preparing agarotriose of the present invention solves the above-described problems by the following method.

First, a pre-treatment process is omitted by applying a β-agarase which usually produces neoagarotetraose which is a precursor for agarotriose during the production of agarotriose, and high yields of agarotriose, 3,6-AHG, and D-Gal are obtained through a two-step enzymatic reaction (that is, an endo type β-agarase, a neoagarobiose hydrolase) under mild conditions.

Second, during the purification of agarotriose, monosaccharides and trisaccharides are separated through a size exclusion Bio-P2 gel column using the difference in degree of polymerization, using a size exclusion chromatography technique, thereby obtaining high-purity agarotriose (FIG. 13B). Since this purification process uses water as a mobile phase without using an organic solvent harmful to the human body and little agarotriose is lost during the purification process, the purification process has an advantage in that purified high-yield agarotriose can be obtained.

The β-agarase degrades any one substrate of agar, agarose, or neoagarohexaose into neoagarobiose and neoagarotetraose which are neoagarooligosaccharides, and a β-agarase of SEQ ID NO: 1 derived from the above-described Bacteroides plebeius DSM 17135 strain may be used, or a heat-resistant agarase of SEQ ID NO: 5, which uses agar or agarose as a substrate to degrade the substrate into neoagarotetraose and neoagarohexaose may be used.

The heat-resistant agarase may be derived from Saccharophagus degradans 2-40^(T), but is not particularly limited thereto.

The heat-resistant agarase may be isolated and purified from a supernatant of a Saccharophagus degradans 2-40^(T) culture product, and may be produced and isolated from strains other than Saccharophagus degradans 2-40^(T) using a genetic engineering recombinant technology, an artificial chemical synthesis method, or the like. When the genetic engineering recombinant technology is used, it may be replaced by a supernatant or supernate fluid of a culture product of a transformed E. coli, but the technology is not particularly limited thereto.

The reaction of any one substrate of agar, agarose, or neoagarohexaose and the β-agarase may be performed at 0 to 200 rpm under a temperature condition of 30 to 60° C. for 5 minutes to 12 hours.

The neoagarobiose hydrolase degrades neoagarobiose and neoagarotetraose into 3,6-AHG, D-Gal, and agarotriose, and a neoagarobiose hydrolase of SEQ ID NO: 2 derived from the above-described Bacteroides plebeius DSM 17135 may be used or an alpha-neoagarobiose hydrolase of SEQ ID NO: 6 derived from Saccharophagus degradans 2-40^(T) may be used.

The Saccharophagus degradans 2-40^(T)-derived alpha-neoagarobiose hydrolase may be isolated and purified from a supernatant or supernate fluid of a culture product of Saccharophagus degradans2-40^(T), and may be produced and purified from strains other than Saccharophagus degradans 2-40^(T) using a genetic engineering recombinant technology, an artificial chemical synthesis method, or the like.

A reaction of a reaction product of the β-agarase and the neoagarobiose hydrolase may be performed at 0 to 200 rpm under a temperature condition of 25 to 45° C. for 30 minutes to 12 hours.

After monosaccharides 3,6-AHG and D-Gal and a trisaccharide agarotriose produced by the neoagarobiose hydrolase are obtained, purified agarotriose with high purity and high yield may be obtained using a size exclusion column.

Hereinafter, the present invention will be described in more detail through the Examples according to the present invention, but the scope of the present invention is not limited by the Examples suggested below.

EXAMPLE1 Experiment of Degrading Agarose by β-Agarase

An enzymatic reaction was performed in order to produce agar-derived oligosaccharides at various degrees of polymerization, including agarotriose from agarose which is a main carbohydrate constituting red algae. First, an enzymatic reaction of Aga16B, which is a S. degradans 2-40^(T)-derived endo-type agarase, was performed using a 1% (w/v) concentration of agarose as a substrate. In this case, the enzymatic reaction of Aga16B was performed at 50° C. and 200 rpm for 2 hours.

As a result of the enzymatic reaction, neoagarotetraose (NeoDP4) and neoagarohexaose (NeoDP6) were produced (FIG. 2B).

Agarotriose (DP3), agaropentaose (DP5), and 3,6-AHG were produced through an enzymatic reaction of a a next-step enzyme, S. degradans 2-40^(T)-derived neoagarobiose hydrolase (SdNABH) and the reaction products as substrates. The SdNABH enzymatic reaction was performed at 30° C. and 200 rpm for 2 hours.

Further, a disaccharide body neoagarobiose (NeoDP2) was produced through an enzymatic reaction of Aga50D, a S. degradans 2-40^(T)-derived exo-type agarase and the Aga16B reaction products as substrates. The Aga50D enzymatic reaction was performed at 30° C. and 200 rpm for 2 hours.

Next, the enzymatic reaction conditions of BpGH16A (BACPLE_01670) which is an endo type β-agarase derived from an intestinal microorganism Bacteroides plebeius DSM 17135 were as follows: enzyme loading amount: 8 mg of BpGH16A/g agarose, buffer: 20 mM Tris-HCl (pH 7.0), and reaction temperature and time: 40° C. and 2 hours.

The enzymatic reaction conditions of a neoagarobiose hydrolase BpGH117 (BACPLE_01671) were as follows: enzyme loading amount: 4 mg of BpGH117/g neoagarobiose, buffer: 20 mM Tris-HCl (pH 7.0), and reaction temperature and time: 40° C. and 2 hours.

As illustrated in FIG. 2C, agarotriose and 3,6-AHG may be produced from agarose through a reaction combination of agar degradation-associated enzymes derived from an intestinal microorganism Bacteroides plebeius DSM 17135. As a result of analyzing the reaction products by thin layer chromatography (TLC), neoagarotetraose (NeoDP4) was produced as a main product (Lane 2) from an agarose substrate (Lane 1) through a BpGH16A (BACPLE_01670) enzymatic reaction. Thereafter, agarotriose and 3,6-AHG were produced (Lane 2) through a BpGH117 (BACPLE_01671) enzymatic reaction. Even when the two enzymes were simultaneously reacted, agarotriose and 3,6-AHG were mainly produced (Lane 3) in the same manner as when the two enzymes were sequentially reacted.

EXAMPLE 2 Recombination and Enzymatic Reaction Experiment of Bacteroides plebeius DSM 17135-Derived Endo Type β-Agarase Enzymes BpGH16A (BACPLE_01670) and BpGH50 (BACPLE_01683) and Neoagarobiose Hydrolase BpGH117 (BACPLE_01671)

As illustrated in FIG. 3, in the case of a Bacteroides plebeius DSM 17135-derived GH50 family enzyme BpGH50 (BACPLE_01683), β-agarase activity was not exhibited.

EXAMPLE 3 Experiment of Producing Agarotriose and AHG from Agarose Substrate Through Enzymatic Reaction of Bacteroides plebeius DSM 17135-Derived Endo Type β-agarase Enzyme BpGH16A (BACPLE_01670) and Neoagarobiose Hydrolase BpGH117(BACPLE_01671)

Oligosaccharides at various degrees of polymerization, neoagarobiose, and 3,6-AHG produced through a reaction of the respective purified recombinant enzymes Aga16B, Aga50D, and SdNABH were purified by size exclusion column chromatography. In this case, Sephadex G-10 was used as a column resin for size-exclusion column chromatography.

As illustrated in FIG. 4, agarotriose and 3,6-AHG were produced from agarose through a reaction of an endo type β-agarase enzyme BpGH16A (BACPLE_01670) and a neoagarobiose hydrolase BpGH117(BACPLE_01671).

EXAMPLE 4 Experiment of Culturing Probiotic Microorganism Bifidobacterium longum subsp. infantis ATCC 15697 Strain by Adopting Respective Purified Sugars as Carbon Sources Using Bioscreen C

In order to prove the prebiotic effects of agar-derived sugars, the cell growth of a Bifidobacterium longum subsp. infantis ATCC 15697 strain which is a Bifidobacterium was monitored using each purified sugar, including agarotriose, as a single carbon source. In this case, as a culture composition, 10 g/L of BactoPeptone, 5 g/L of a yeast extract, 2 g/L of K₂HPO₄ anhydride, 5 g/L of Na acetate anhydride, 2 g/L of NH₄ citrate tribasic, 0.2 g/L of Mg sulfate heptahydrate, 0.05 g/L of Mn sulfate, 1 mL/L of Tween 80 (polysorbate 80), 0.5 g/L of cysteine, and 5 g/L of each purified sugar were used and cultured at 37° C.

As illustrated in FIG. 5, it was confirmed that the Bifidobacterium longum subsp. infantis ATCC 15697 strain selectively fermented only agarotriose among various purified sugars.

EXAMPLE 5 Analysis of Agarotriose Fermentation Profile of Bifidobacterium longum subsp. infantis ATCC 15697 Strain

In order to monitor fermentation products, a Bifidobacterium longum subsp. Infantis ATCC 15697 strain was cultured under a test tube condition.

As illustrated in FIG. 6, the Bifidobacterium longum subsp. infantis ATCC 15697 degraded agarotriose into galactose and neoagarobiose under a carbon source at a concentration of 5 g/L agarotriose, and galactose was fermented in cells to produce acetic acid. The neoagarobiose was secreted and accumulated outside the cells without being degraded in the cells any more.

EXAMPLE 6 Degradation Experiments of Agarotriose and Neoagarobiose Using Crude Enzyme Solution of Bifidobacterium longum subsp. infantis ATCC 15697 Strain

In order to confirm the metabolic pathway of agarotriose, an experiment was performed on a crude enzyme solution of a Bifidobacterium longum subsp. infantis ATCC 15697 strain. For this purpose, cells and the medium were separated by centrifugation (14,000 rpm, 5 minutes, 4° C.) of a culture solution of Bifidobacterium longum subsp. infantis ATCC 15697 cultured under an agarotriose condition. An extracellular crude enzyme was obtained by ammonium sulfate precipitation of a supernatant. Further, for a cell-free extract including an intracellular crude enzyme, a supernatant crude enzyme was obtained by re-suspending cells in a 20 mM Tris-HCl buffer, and then lysing the cells by sonication, and centrifuging the lysate. During the crude enzyme experiment, 2 mg/mL of the crude enzyme and 2 mg/mL of agarotriose as a substrate were used to perform a reaction under an enzymatic reaction condition of 30° C. and 200 rpm in a 20 mM Tris-HCl buffer (pH 7.0) for 2 hours.

As illustrated in FIG. 7, it was confirmed that a β-galactosidase reaction of degrading agarotriose into galactose and neoagarobiose occurred in the cell-free extract including an intracellular crude enzyme. In addition, it was confirmed that the activity of the crude enzyme against neoagarobiose was not exhibited.

EXAMPLE 7 Recombinant Protein Production and Enzymatic Reaction Experiments of Four β-Galactosidase-Encoding Genes (Blon_2016, Blon_2123, Blon_2334, and Blon_2416) of a Bifidobacterium longum subsp. infantis ATCC 15697 Strain

In order to confirm which enzyme gene had the activity of degrading agarotriose, after all of the four β-galactosidases of the Bifidobacterium longum subsp. infantis ATCC 15697 were cloned, the enzymatic activity was tested by overexpressing the four β-galactosidases in E. coli and purifying each enzyme protein.

As illustrated in FIG. 8, it was confirmed that proteins of two enzyme genes Blon_2016 and Blon_2334 exhibited activity.

EXAMPLE 8 Experiment of the Fermentation Ability of Agarotriose by Other Strains Belonging to Bifidobacterium longum subsp. Infantis

In order to confirm whether agarotriose also had prebiotic effects on probiotic microorganisms other than a Bifidobacterium longum subsp. infantis ATCC 15697 strain, Bifidobacterium longum subsp. infantis ATCC 17930, Bifidobacterium longum subsp. infantis ATCC 15702, B. bifidum DSM 20082, and B. kashiwanohense DSM 21854 were cultured under agarotriose single carbon source conditions.

As illustrated in FIGS. 9 and 10, all four probiotic microorganisms metabolized agarotriose and degraded agarotriose into galactose and neoagarobiose in the same manner as in Bifidobacterium longum subsp. infantis ATCC 15697, and then acetic acid was produced by fermenting galactose.

EXAMPLE 9 Stability Test of Agarotriose Against Artificial Gastric Juice

In order to test whether agarotriose could reach the intestines without being degraded, agarotriose was reacted in artificial gastric juice for each time, and then it was confirmed whether agarotriose was degraded, using TLC and HPLC.

As illustrated in FIG. 11, it was confirmed that after being reacted at 37° C. for 3 hours, 80% or more of agarotriose remained.

From the result, it was firstly confirmed that agarotriose is a novel red algae-derived prebiotic, and a material that is selectively fermented by probiotics. Agarotriose may be produced by enzymatic actions of agarases and NABH from marine derived-S. degradans 2-40^(T) or intestinal microorganism-derived Bacteroides plebeius (FIG. 12). Agarotriose is transported into cells by the ABC transporter-related gene of the probiotic Bifidobacter, and is degraded into galactose and neoagarobiose by intracellular β-galactosides, and galactose is used for acetic acid fermentation. In addition, neoagarobiose may be degraded into galactose and 3,6-AHG in the intestines by a neoagarobiose hydrolase from an intestinal microorganism Bacteroides plebeius. Since AHG is known as a bioactive material having a colon cancer prevention effect and anti-inflammatory functionality, agarotriose may exhibit not only prebiotic activity, but also colon cancer prevention and anti-inflammatory bioactivities due to AHG produced through the metabolism by intestinal microorganisms Bifidobacter and Bacteroides plebeius (FIG. 12).

EXAMPLE 10 Production of BACPLE_01670 and NABH Recombinant Enzymes

A Bacteroides plebeius-derived β-agarase hydrolase BACPLE_01670 gene was introduced into E. coli BL21 (DE3) using a pET21a vector. In order to pre-culture the recombinant E. coli introduced the gene, the recombinant E. coli was cultured at 37° C. for 9 hours in a 10 mL LB broth containing 100μg/mL of ampicillin in a 50-mL-conical tube. Thereafter, after 10 ml of the pre-culture solution was inoculated into 1 L of the main culture solution having the same medium composition, 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) was added thereto when the optical density value showed growth to a mid-exponential step (OD 0.4 to 0.6), and an intracellular protein was expressed by induction at 16° C. for 16 hours. Thereafter, the cell culture solution was transferred to a 500 mL-tube and centrifuged at 10,000 rpm at 4° C. for 30 minutes, and then cells were obtained. In order to prevent protein denaturation, cells collected in 30 mL of a Tris buffer (20 mM Tris-HCl, pH 7.0) were freed again, and the cells were lysed using a sonicator. Thereafter, the cells were centrifuged at 16,000 rpm at 4° C. for 1 hour. The proteins were purified using a HisTrap column (5 ml GE Healthcare), and then the size of each purified protein was confirmed using an SDS-PAGE gel. The salt (imidazole) used for protein purification was removed using a desalting column. The concentration of the recombinant protein from which the salt was removed was quantified by a BCA analysis method.

Next, a Saccharophagus degradans 2-40^(T)-derived alpha-neoagarobiose hydrolase NABH gene was introduced into E. coli BL21 (DE3) using a pET21a vector, and the recombinant protein was prepared as described above.

EXAMPLE 11 Enzymatic Reaction of BACPLE_01670 and NABH

During the BACPLE_01670 enzymatic reaction, a 1% (w/v) concentration agarose was used as a substrate, and a reaction was performed under conditions of 50° C. and 100 rpm for 10 hours in a 20 mM Tris-HCl buffer (pH 7.0).

An NABH enzymatic reaction was performed using BACPLE_01670 enzymatic reaction products neoagarotetraose and neoagarobiose as substrates, and an enzymatic reaction was performed under conditions of 37° C. and 100 rpm for 10 hours.

The reaction products after the enzymatic reaction in each step were analyzed by TLC. For the TLC analysis conditions, 1μl of enzymatic reaction products were loaded onto a silica gel plate as a stationary phase, n-butanol: ethanol: water at 3:1:1 (v/v/v) as a mobile phase solvent was eluted for 1 hour, and then colors were developed using 10% sulfuric acid in ethanol and 0.2% 1,3-dihydroxynaphthalene in ethanol.

As illustrated in FIG. 14A, agarose was degraded into neoagarooligosaccharides through an enzymatic reaction of an endo type β-agarase BACPLE_01670, and in this case, the main products were neoagarobiose and neoagarotetraose corresponding to DP2 and DP4 as a degree of polymerization (DP). Thereafter, through an enzymatic reaction of an alpha-agarase neoagarobiose hydrolase (NABH), trisaccharides agarotriose and 3,6-AHG were produced from DP4, and D-galactose and 3,6-AHG were produced from DP2.

EXAMPLE 12 HPLC Analysis of BACPLE_01670 Enzymatic Reaction Products

Materials produced during the BACPLE_01670 enzymatic reaction were neoagarotetraose (DP4) and neoagarobiose (DP2)(FIG. 14B). Among them, a precursor for making agarotriose is neoagarotetraose, and the more the DP4 product, the more agarotriose may be obtained. In order to determine the production ratio of DP4 from BACPLE_01670, the production ratio was calculated using an HPLC KS-802 size exclusion column.

As illustrated in FIG. 15, regarding the reaction products of BACPLE_01670, a result of 0.795 g of neoagarotetraose (0.795 g neoagarotetraose/g agarose) and 0.205 g of neoagarobiose (0.205 g neoagarobiose/g agarose) from 1 g of agarose was obtained.

EXAMPLE 13 Separation of DP3 (Agarotriose) and DPI (3,6-AHG, D-Gal) Using Size-Exclusion Column (Bio Gel-P2 Column)

The final reaction products obtained from Examples 10 and 11 were 3,6-AHG and D-Gal, and agarotriose, and a sugar separation column was used to separate 3,6-AHG and D-Gal thereamong from agarotriose. The machine AKTAprime (GE Healthcare) was used. For a mobile phase used to separate the sugars, a column was stabilized for 10 minutes by flowing tertiary distilled water at a flow rate of 0.3 mL/min, and then 1 ml of a solution flowing through the column after injecting 2 mL of the reaction product was transferred per 2 mL-Eppendorf tube, and analyzed through TLC. The TLC analysis conditions were the same as those in

EXAMPLE 11

As illustrated in FIG. 16, it could be confirmed that as a result of analyzing samples collected by fraction by TLC, DP3 (agarotriose) and DP1 (3,6-AHG, D-Gal) were separated.

EXAMPLE 14 HPLC Quantitative Analysis of Yield and Purity of Agarotriose From Agarose by Enzymatic Saccharification and Separated by Size Exclusion Column

After the agarotriose obtained by the sugar separation column in Example 13 was confirmed by TLC, the fraction of agarotriose with high purity was collected. Fractions Nos. 55 to 61 were collected in 15 mL-conical tubes and stirred and well mixed. Thereafter, yield and purity were analyzed through an HPLC KS-802 column by sampling a part of 7 mL.

As illustrated in FIG. 17, it was confirmed that 0.4 g of agarotriose was obtained from 1 g of agarose (0.4 g NAB/g agarose), and about 90.2% of the sample was agarotriose.

The present invention can be used as an anti-cancer or anti-inflammatory agent in the fields of food and medicine based on prebiotic characteristics of agarotriose. 

1. A medicine composition comprising: one or more substrates selected from the group consisting of agar, agarose, neoagarohexaose, and agarotriose; a Bacteroides plebeius strain; and a Bifidobacterium strain.
 2. The medicine composition of claim 1, wherein the Bacteroides plebeius strain comprises a Bacteroides plebeius DSM 17135 strain.
 3. The medicine composition of claim 1, wherein the Bifidobacterium strain is selected from the group consisting of Bifidobacterium longum subsp. infantis ATCC 15697, Bifidobacterium longum subsp. infantis ATCC 17930, Bifidobacterium longum subsp. infantis ATCC 15702, B. bifidum DSM 20082, and B. kashiwanohense DSM
 21854. 4. The medicine composition of claim 1, wherein the medicine composition degrades a substrate into 3,6-anhydro-L-galactose by a β-agarase of SEQ ID NO: 1 and a neoagarobiose hydrolase of SEQ ID NO: 2 derived from a Bacteroides plebeius DSM 17135 strain, respectively and a β-galactosidase of SEQ ID NO: 3 or 4 derived from a Bifidobacterium longum subsp. infantis ATCC 15697 strain.
 5. The medicine composition of claim 1, wherein the medicine composition is to prevent or treat a cancer or an inflammatory disease.
 6. A food composition comprising: one or more substrates selected from the group consisting of agar, agarose, neoagarohexaose, and agarotriose; a Bacteroides plebeius strain; and a Bifidobacterium strain.
 7. The food composition of claim 6, wherein the Bacteroides plebeius strain comprises a Bacteroides plebeius DSM 17135 strain.
 8. The food composition of claim 6, wherein the Bifidobacterium strain is selected from the group consisting of Bifidobacterium longum subsp. infantis ATCC 15697, Bifidobacterium longum subsp. infantis ATCC 17930, Bifidobacterium longum subsp. infantis ATCC 15702, B. bifidum DSM 20082, and B. kashiwanohense DSM
 21854. 9. The food composition of claim 6, wherein the food composition degrades a substrate into 3,6-anhydro-L-galactose by a β-agarase of SEQ ID NO: 1 and a neoagarobiose hydrolase of SEQ ID NO: 2 derived from a Bacteroides plebeius DSM 17135 strain, respectively and a β-galactosidase of SEQ ID NO: 3 or 4 derived from a Bifidobacterium longum subsp. infantis ATCC 15697 strain.
 10. The food composition of claim 6, wherein the food composition is to prevent or alleviate a cancer or an inflammatory disease.
 11. A method for producing agarotriose, the method comprising: reacting a reaction product with a neoagarobiose hydrolase of SEQ ID NO: 2 or 6, wherein the reaction product is obtained by reacting any one substrate of agar, agarose or neoagaroheaose with a β-agarase of SEQ ID NO: 1 or 5; and purifying agarotriose from the resulting product through a size-exclusion column.
 12. The method of claim 11, wherein the β-agarase of SEQ ID NO: 1 is an enzyme that is derived from a Bacteroides plebeius DSM 17135 strain, and uses agar, agarose, or neoagarohexaose as a substrate to degrade the substrate into neoagarotetraose and neoagarobiose.
 13. The method of claim 11, wherein a reaction of the substrate with the β-agarase is performed at 0 to 200 rpm under a temperature condition of 30 to 60° C. for 5 minutes to 12 hours.
 14. The method of claim 11, wherein the neoagarobiose hydrolase of SEQ ID NO: 2 is an enzyme that is derived from a Bacteroides plebeius DSM 17135 strain, and uses neoagarotetraose or neoagarobiose as a substrate to degrade the substrate into agarotriose, galactose, or 3,6-anhydro-L-galactose.
 15. The method of claim 11, wherein a reaction of a reaction product of the substrate and the β-agarase with the neoagarobiose hydrolase is performed at 0 to 200 rpm under a temperature condition of 25 to 45° C. for 30 minutes to 12 hours.
 16. A method for treating cancer or an inflammatory disease, the method comprising: administering a therapeutically effective amount of a medicine composition to a subject, wherein the medicine composition comprises: one or more substrates selected from the group consisting of agar, agarose, neoagarohexaose, and agarotriose; a Bacteroides plebeius strain; and a Bifidobacterium strain.
 17. The method of claim 16, wherein the Bacteroides plebeius strain comprises a Bacteroides plebeius DSM 17135 strain.
 18. The method of claim 16, wherein the Bifidobacterium strain is selected from the group consisting of Bifidobacterium longum subsp. infantis ATCC 15697, Bifidobacterium longum subsp. infantis ATCC 17930, Bifidobacterium longum subsp. infantis ATCC 15702, B. bifidum DSM 20082, and B. kashiwanohense DSM
 21854. 19. The method of claim 16, wherein the cancer is any one of colon cancer, cervical cancer, breast cancer, gastric cancer, and liver cancer. 